| |
Arm A (n = 32)
|
Arm B (n = 31)
|
Total (n = 63)
|
|---|
| |
n
|
Percent
|
n
|
Percent
|
n
|
Percent
|
|---|
|
Age
| | | | | | |
|
Median
| |
70
| |
65
| |
68
|
|
Range
| |
50-89
| |
45-80
| |
45-89
|
|
Race
| | | | | | |
|
White
|
30
|
94%
|
28
|
90%
|
58
|
92%
|
|
Black
|
1
|
3%
|
3
|
10%
|
4
|
6%
|
|
Hispanic
|
1
|
3%
|
0
|
0%
|
1
|
2%
|
|
ECOG PS
| | | | | | |
|
0
|
15
|
47%
|
17
|
55%
|
32
|
51%
|
|
1
|
16
|
50%
|
12
|
39%
|
28
|
44%
|
|
2
|
1
|
3%
|
2
|
6%
|
3
|
5%
|
|
Extent of Disease
| | | | | | |
|
Measurable, Non-Osseous Disease Present
|
14
|
44%
|
13
|
42%
|
27
|
43%
|
|
Evaluable, Osseous Disease Present
|
28
|
88%
|
30
|
97%
|
58
|
92%
|
|
Evaluable, Non-Osseous Disease Present
|
13
|
41%
|
12
|
39%
|
25
|
40%
|
|
Elevated PSA
|
32
|
100%
|
30
|
97%
|
62
|
98%
|
|
Metastatic Disease
| | | | | | |
|
Lung
|
4
|
13%
|
4
|
13%
|
8
|
13%
|
|
Liver
|
3
|
9%
|
3
|
10%
|
6
|
10%
|
|
Bone
|
28
|
88%
|
29
|
94%
|
57
|
90%
|
|
Bone Marrow
|
0
|
0%
|
1
|
3%
|
1
|
2%
|
|
Pleura
|
1
|
3%
|
0
|
0%
|
1
|
2%
|
|
Other
|
11
|
34%
|
9
|
29%
|
20
|
32%
|
|
Prior Treatment
| | | | | | |
|
Orchiectomy
|
10
|
31%
|
7
|
23%
|
17
|
27%
|
|
Prostatectomy
|
17
|
53%
|
15
|
48%
|
32
|
51%
|
|
Other Surgery
|
19
|
59%
|
20
|
65%
|
39
|
62%
|
|
Radiation Therapy
|
18
|
56%
|
20
|
65%
|
38
|
60%
|
|
Hormonal Therapy
|
31
|
97%
|
29
|
94%
|
60
|
95%
|
|
Biologic Response Modifier
|
4
|
13%
|
2
|
6%
|
6
|
10%
|
